GNS561-CL-I-Q-0211: Phase 1/2 Study to Evaluate the Safety, Activity, and Pharma
- This topic has 0 replies, 1 voice, and was last updated 4 years, 7 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
GNS561-CL-I-Q-0211: Phase 1/2 Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients with Primary Liver Cancer which includes Intrahepatic cholangiocarcinoma patients
https://clinicaltrials.gov/ct2/show/NCT03316222
Gavin
Viewing 1 post (of 1 total)
- The forum ‘Clinical Trials’ is closed to new topics and replies.